TACR2 Antibody

What is TACR2 and what functional domains are important for antibody generation?

TACR2, also known as Neurokinin 2 Receptor (NK2R), is a G protein-coupled receptor for the tachykinin neurokinin A (neuropeptide substance K). It belongs to the tachykinin receptor family characterized by seven hydrophobic transmembrane regions and interactions with G proteins that activate a phosphatidylinositol-calcium second messenger system .

TACR2 antibodies are commonly generated against several key domains:

For optimal experimental design, researchers should select antibodies targeting domains relevant to their specific research questions, considering factors such as species reactivity and post-translational modifications .

How can researchers validate the specificity of TACR2 antibodies in their experimental systems?

Validating antibody specificity is critical for reliable results. A methodological approach includes:

• Positive control selection: Use cell lines with documented TACR2 expression (e.g., HeLa, PC-3 cells have shown positive Western blot signals)

• Multiple techniques validation: Cross-validate across different methods:

  • Western blot: Look for bands at the expected molecular weight (44 kDa)

  • Immunohistochemistry: Compare staining patterns with published literature

  • Peptide competition assays: Pre-incubate antibody with immunizing peptide to confirm specificity

• Genetic validation approaches:

  • Use TACR2 knockout models: The Tacr2−/− mouse model described in the literature can serve as an excellent negative control

  • siRNA knockdown: Compare antibody signal in knockdown vs. control samples

• Cross-antibody validation: Use multiple antibodies targeting different epitopes of TACR2 and compare the detection patterns

For advanced applications, especially when studying TACR2 in novel systems, researchers should consider both pharmacological inhibition using selective NK2R antagonists and genetic ablation approaches to confirm antibody specificity .

What are the optimal conditions for Western blot applications using TACR2 antibodies?

Western blot protocols should be optimized for TACR2 detection based on the following parameters:

Troubleshooting note: If experiencing high background, researchers should consider:

• Increasing antibody dilution

• Adding longer washing steps

• Using antigen affinity-purified antibodies, which typically provide cleaner results (e.g., "The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin")

For phospho-specific detection, samples should be collected after appropriate stimulation with NK2R agonists, such as GR 64349, and phosphatase inhibitors must be included in the lysis buffer .

How should researchers design IHC-based experiments to investigate TACR2 expression in tissues?

For successful immunohistochemical detection of TACR2:

• Tissue processing considerations:

  • Fixation: 4% paraformaldehyde is generally suitable

  • Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

  • Section thickness: 5-8 μm sections typically provide good results

• Protocol optimization:

  • Primary antibody dilution: Start with manufacturer's recommendation (typically 1:100-1:200)

  • Incubation: Overnight at 4°C often yields best signal-to-noise ratio

  • Detection system: DAB-based detection for brightfield; fluorescence-conjugated secondary antibodies for IF

• Controls to include:

  • Positive control tissues: Based on literature, examine tissues with known TACR2 expression

  • Negative controls: Primary antibody omission and isotype controls

  • Comparative controls: When possible, include Tacr2−/− tissues

• Co-localization studies:

  • TACR2 is expressed in various tissues including neural and immune cells

  • Double staining with cell-type specific markers helps identify TACR2-expressing populations

Research has shown TACR2 expression in multiple tissue types, with applications validating antibody use in immunohistochemistry for human, rat, and mouse samples . When interpreting results, consider that TACR2 expression may be modulated by inflammatory stimuli or stress conditions, as suggested by IFN-γ-mediated induction of NK2R expression .

What approaches should be used to study TACR2 phosphorylation and activation in experimental systems?

Studying TACR2 phosphorylation requires specialized techniques:

• Phospho-specific antibody applications:

  • Western blot using phospho-specific antibodies targeting Ser345/Thr346

  • Comparison between basal and stimulated conditions using selective NK2R agonists

• Functional readouts of TACR2 activation:

  • Calcium mobilization assays: TACR2 activation triggers Ca²⁺ release

  • ERK1/2 phosphorylation: Downstream of TACR2 signaling

  • IκBα degradation: Used as an indicator of NF-κB pathway activation

• Receptor internalization studies:

  • Immunofluorescence before and after agonist treatment

  • Surface biotinylation assays to quantify receptor internalization

• Pharmacological tools:

  • Selective NK2R agonist: GR 64349 has >1,000-fold selectivity over NK1R and >300-fold over NK3R

  • NK2R antagonists: Used to confirm specificity of signaling responses

Research indicates that TACR2 signaling is involved in multiple pathways. For example, in CD8+ T cells, "NKA stimulation combined with anti-CD3 monoclonal antibody treatment significantly augmented IFN-γ and granzyme B production," and "ERK1/2 phosphorylation and IκBα degradation in activated CD8+ T cells were suppressed under NK2R deficiency" . These findings suggest relevant readouts when studying TACR2 activation in immune contexts.

How is TACR2 involved in cancer progression and immune responses?

Research demonstrates significant connections between TACR2 and cancer immunology:

• TACR2 in anti-tumor immunity:

  • IFN-γ–STAT1 signaling induces NK2R expression in CD8+ T cells

  • NK2R-mediated signaling enhances antitumor effector T cell function

  • NK2R deficiency significantly augments metastatic colonization of colon cancer cells in the liver

• Mechanistic pathways:

  • NKA signaling through NK2R enhances IFN-γ and granzyme B production in CD8+ T cells

  • This occurs through activation of ERK1/2 and NF-κB signaling pathways

  • In knockout models, "tumor growth was significantly increased in NK2R-deficient mice compared with wild-type mice"

• Experimental findings:

  • Poly I:C treatment induces type I and II IFNs and suppresses tumorigenesis in a STAT1-dependent manner

  • This anti-tumor effect is diminished by CD8+ T cell depletion

  • NK2R deficiency abolishes the antitumor effects of poly I:C

These findings suggest that targeting the TACR2 pathway could be therapeutically relevant in enhancing anti-tumor immunity. Researchers studying this area should consider both genetic approaches (using Tacr2−/− models) and pharmacological interventions with selective NK2R agonists to further elucidate these mechanisms.

What is the role of TACR2 in neurological functions and anxiety regulation?

TACR2 has significant roles in neurological function:

• TACR2 expression in central nervous system:

  • TACR3 (related receptor) is widely expressed in brain regions including hippocampus

  • Interconnection between tachykinin signaling and anxiety regulation

• Relationship with sex hormones:

  • Hippocampal TACR3 expression is modulated by testosterone

  • Sexual development in males is associated with increased hippocampal TACR3 expression

  • This coincides with elevated serum testosterone and reduced anxiety

• Synaptic plasticity effects:

  • TACR3 inhibition affects CaMKII activation and AMPA receptor phosphorylation

  • Influences spine density and neuronal connectivity

  • Deficient TACR3 activity leads to impaired long-term potentiation (LTP)

• Experimental evidence:

  • "Downregulation of TACR3 was observed in the lateral habenula of mice showing anxiety-like behaviors"

  • "TACR3 overexpression in the same area significantly reversed such anxiety-like behaviors"

  • "In males, sexual development is associated with a substantial increase in hippocampal TACR3 expression, coinciding with elevated serum testosterone and a significant reduction in anxiety"

While this research focuses on TACR3, the related receptor TACR2 likely has similar neurological functions, though less extensively characterized. Researchers interested in TACR2's neurological functions should design experiments that consider potential overlapping roles among tachykinin receptors and their interactions with hormonal systems.

How does TACR2 contribute to metabolic regulation, and what therapeutic potential does it have?

TACR2 has emerging significance in metabolic regulation:

• Dual metabolic effects:

  • TACR2 (NK2R) activation suppresses appetite centrally

  • Simultaneously increases energy expenditure peripherally

  • This combination addresses two key aspects of metabolic disorders

• Genetic associations:

  • TACR2 has genetic links to obesity and glucose control

  • Represents a single receptor target that leverages both energy-expending and appetite-suppressing mechanisms

• Therapeutic development challenges:

  • Neurokinin A (NKA), the endogenous ligand, is short-lived and lacks receptor specificity

  • Development of selective, long-acting NK2R agonists has therapeutic potential

  • These agonists could potentially be administered once-weekly in humans

• Preclinical efficacy data:

  • In mice: NK2R agonists elicit weight loss through:

    • Increased energy expenditure

    • Non-aversive appetite suppression (bypassing leptin signaling)

    • Enhanced insulin sensitization

  • In diabetic obese macaques: NK2R activation:

    • Significantly decreases body weight

    • Reduces blood glucose, triglycerides, and cholesterol

    • Ameliorates insulin resistance

This research suggests TACR2 as a promising single-target approach for treating obesity and type 2 diabetes, offering advantages over current multi-receptor agonist approaches .

How do different tachykinin receptors interact, and what methodological approaches can distinguish their functions?

Understanding the overlapping functions of tachykinin receptors requires careful experimental design:

• Receptor similarities and differences:

  • TACR1, TACR2, and TACR3 all belong to the tachykinin receptor family

  • They respond to partially overlapping ligands with different affinities

  • Research shows "partially overlapping and redundant functions with other tachykinin receptors"

• Pharmacological approaches:

  • Selective agonists:

    • NK1R agonist: GR 73632

    • NK2R agonist: GR 64349 (>1,000-fold selectivity over NK1R, >300-fold over NK3R)

    • NK3R agonist: senktide

  • Selective antagonists:

    • NK3R antagonist: SB 222200

• Genetic model evidence:

  • Tacr2−/− mice showed partially reduced LH responses to an NK2R agonist

  • These responses were "abrogated after blockade of NK3R in Tacr2−/− males"

  • This suggests functional compensation between receptors

• Experimental design recommendations:

  • Combined pharmacological and genetic approaches

  • Sequential blockade of multiple receptors

  • Assessment of combined knockouts/knockdowns

  • Cross-species validation (considering possible species differences in receptor functions)

Research indicates congenital ablation of Tacr2 "partially suppressed basal and stimulated LH secretion, with moderate reproductive impact," highlighting the complex interplay between these receptors and suggesting redundant mechanisms .

What considerations are important when selecting between different detection methods for TACR2?

Researchers should consider multiple factors when selecting detection methods:

• Antibody-based detection methods comparison:

• Non-antibody alternatives:

  • Ligand binding assays with labeled NK2R agonists

  • Reporter gene assays for functional studies

  • RNA-based detection (qPCR, RNA-seq, RNAscope)

• Method selection guidance:

  • Research question: Expression level vs. localization vs. activation state

  • Sample type: Cultured cells, tissue sections, biological fluids

  • Detection sensitivity requirements

  • Need for quantification vs. localization information

• Validation strategies across methods:

  • Confirm protein expression with both antibody and non-antibody methods

  • Correlate protein detection with mRNA expression

  • Validate functional studies with both genetic and pharmacological approaches

For comprehensive characterization, researchers are advised to employ multiple complementary techniques, especially when studying TACR2 in novel contexts or developing new therapeutic approaches .

What are the critical considerations for studying species differences in TACR2 function and expression?

Species variations in TACR2 require careful experimental planning:

• Known species similarities and differences:

  • Sequence homology: Human TACR2 shares high identity with:

    • Gorilla, Gibbon, Monkey, Marmoset (100%)

    • Bovine, Rabbit (94%)

    • Horse, Pig (88%)

  • Functional conservation may not perfectly match sequence homology

• Cross-species reactivity of antibodies:

  • Many antibodies show reactivity across human, rat, and mouse TACR2

  • Some antibodies have predicted reactivity with Pig, Bovine, Horse, Sheep, Rabbit, Dog

  • Validation is essential when using antibodies across species

• Functional assay considerations:

  • Pharmacological differences in ligand binding affinity

  • Variations in downstream signaling pathways

  • Different physiological roles in different species

• Experimental design recommendations:

  • Begin with species-specific positive controls

  • Validate antibodies for cross-reactivity experimentally

  • Consider species-specific differences in experimental design

  • Include appropriate genetic models (Tacr2−/− mice) for definitive validation

Researchers should note that while TACR2 antibodies often show cross-reactivity across species, the functional implications and cellular contexts may differ. For example, stimulation of NK2R elicited luteinizing hormone responses in mice, while the reproductive impact of TACR2 ablation appeared more moderate than in some other species studied .

What are emerging approaches for studying TACR2 beyond traditional antibody applications?

Cutting-edge methodologies for TACR2 research include:

• Advanced imaging techniques:

  • Super-resolution microscopy for precise receptor localization

  • FRET/BRET assays for receptor-protein interactions

  • Live-cell imaging with tagged receptors to study trafficking

• Genetic engineering approaches:

  • CRISPR/Cas9 for endogenous tagging or knockout

  • Knock-in reporter lines (e.g., TACR2-GFP)

  • Conditional/inducible knockout models to study temporal effects

• Systems biology approaches:

  • Proteomics to identify TACR2 interactome

  • Transcriptomics to analyze downstream signaling effects

  • Metabolomics to study effects on cellular metabolism

• Therapeutic development tools:

  • Development of long-acting NK2R agonists with improved specificity

  • Biased ligand development targeting specific signaling pathways

  • Antibody-drug conjugates for targeting TACR2-expressing cells

Recent research demonstrated the development of "selective, long-acting NK2R agonists with potential for once-weekly administration in humans" for metabolic disease applications . Additionally, multielectrode array techniques have been used to study neuronal activity patterns in relation to tachykinin receptor function, showing "stronger cross-correlation of firing was evident among neurons following TACR3 inhibition" . These approaches represent the cutting edge of TACR2 research methodologies.